ArticleIrish journal of medical science2026
The significance of the pregnancy-associated plasma protein A and insulin like growth factor-1 system on the risk of atherosclerotic cardiovascular diseases.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe pregnancy associated plasma protein A (PAPP-A) is present at high levels in serum of pregnant women with a potential role in atherosclerosis. PAPP-A is a metalloproteinase with a well-established role in releasing bioactive insulin-like growth factor-1 (IGF-1). Little is known about their significance as biomarkers of Atherosclerotic cardiovascular diseases (ASCVDs) risk and their association with the need of revascularization through percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG).
aimsTo evaluate plasma levels of PAPP-A and IGF-1 in patients with increased ASCVDs risk and examine if they are associated with CAD severity as indicated by the need for revascularization.
methodsPatients presented to the catheterization lab were grouped based on ASCVDs risk into low, moderate, high, and very high. Plasma levels of PAPP-A and IGF-1 were assessed using ELISA and correlated with ASCVDs risk and the requirement for revascularization.
resultsPlasma PAPP-A and IGF-1 levels were increased in CAD patients, with elevated concentrations in MI patients. A stepwise elevation in plasma PAPP-A and IGF-1 levels was observed with the elevated ASCVDs risk. An independent association was observed between plasma PAPP-A and IGF-1 levels, ASCVDs risk, and the requirement for revascularization.
conclusionOur study demonstrates that plasma levels of PAPP-A and IGF-1 are associated with elevated ASCVDs risk and may serve as potential biomarkers for monitoring disease development. Their association with disease severity suggests a potential role in identifying patients more likely to undergo revascularization, pending further prospective validation.
Indexed as
Identifiers
42766089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.